Immunomodulation: The future of allergy and asthma treatment

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 1, 2004, Pages 63-67

  Bloebaum, R Matthew ^a   Grant, J Andrew ^a   Sur, Sanjiv ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Allergic disease; Asthma; Immunomodulation; T helper type 2 cytokines

Indexed keywords

ALPHA2A INTERFERON; AMPHOTERICIN B; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR3; DINUCLEOTIDE; EFALIZUMAB; ENZYME INHIBITOR; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 9; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CCR3; OMALIZUMAB; PROTEIN KINASE LYN; PROTEIN KINASE LYN INHIBITOR; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNMETHYLATED CYTOSINE GUANINE DINUCLEOTIDE;

ALLERGIC DISEASE; ANTIGEN BINDING; ASTHMA; CLINICAL TRIAL; CPG ISLAND; DOSE RESPONSE; DOWN REGULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; FEVER; FLU LIKE SYNDROME; GENE THERAPY; HEADACHE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; NAUSEA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VOMITING;

ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ASTHMA; CELL DIFFERENTIATION; DOWN-REGULATION; FORECASTING; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTION FACTORS;

EID: 4143144096     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200402000-00013     Document Type: Review

References (38)

1. World Health Organization. Fact sheet no. 206. Geneva: WHO; January 2000.
2. National Asthma Education and Prevention Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 2002; 100:S145-S219.
3. Busse W, Corren J, Lanier BO, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
4. Leung DYM, Sampson HA, Yunginger JW, et al. Effects of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986-993. A study showing the future potential of anti-IgE therapy.
5. Corren J, Casale T, Ceniz Y, et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111:87-90. This study shows the value of anti-IgE therapy for the severe asthmatic patient.
6. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111:278-284. Another study that validates the value of anti-IgE therapy for the severe asthmatic patient.
7. Gauvreau GM, Becker AB, Boulet LP, et al. The effects of an anti-ed11 mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003; 112:331-338.
8. Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin Immunol 2002; 103:231-242.
9. Busse WW, Lemanske RF. Asthma. N Engl J Med 2001; 344:350-362.
10. Leonard P, Sur S. Asthma: future directions. Med Clin North Am 2002; 86:1-26. An excellent review of the ongoing investigations into asthma therapies.
11. Jaffe HA, Buhl R, Mastrangeli A, et al. Organ specific cytokine therapy: local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J Clin Invest 1991; 88:297-302.
12. Li XM, Chopra RK, Chou TY, et al. Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice. J Immunol 1996; 157:3216-3219.
13. Gavett SH, O'Hearn DJ, Li X, et al. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995; 182:1527-1546.
14. Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149-2153.
15. Sur S, Wild JS, Choudhury BK, et al. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999; 162:6284-6293.
16. Anderson GP, Coyle AJ. TH2 and TH2-like cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol Sci 1994; 15:324-332.
17. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-970.
18. Hamelmann E, Takeda K, Schwarze J, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol 1999; 21:480-489.
19. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148.
20. Menzies-Gow A, Flood-Page R, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111:714-719. An important study showing the effectiveness of anti-IL-5 therapy.
21. Buttner C, Lun A, Splettstoesser T, et al. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003; 21:799-803. This study shows the specificity of anti-IL-5 therapy.
22. Louahed J, Toda M, Jen J, et al. Interleukin-9 up-regulates mucus expression in the airways. Am J Respir Cell Mol Biol 2000; 22:649-650.
23. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-2261.
24. Lamkhioued B, Abdelilah SG, Hamid Q, et al. The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells. J Immunol 2003; 170:537-547. A study showing the value of CCR3 as a possible target for therapy.
25. White JR, Lee JM, Dede K, et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem 2000; 275:36626-36631.
26. De Lucca GV, Kim UT, Johnson C, et al. Discovery and structure-activity relationship of N-(ureidoatkyl)-benzyl piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. J Med Chem 2002; 45:3794-3804.
27. Warrior U, McKeegan EM, Rottinghaus SM, et al. Identification and characterization of novel antagonists of the CCR3 receptor. J Biomol Screen 2003; 8:324-331.
28. Wacker DA, Santella JB III, Gardner DS, et al. CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships. Bioorg Med Chem Lett 2002; 12:1785-1789.
29. Saeki T, Ohwaki K, Naya A, et al. Identification of a potent and nonpeptidyl CCR3 antagonist. Biochem Biophys Res Commun 2001; 281:779-782.
30. Eisner J, Petering H, Hochstetter R, et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 1997; 27:2892-2898.
31. Sehmi R, Dorman S, Baatjes A, et al. Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. Immunology 2003; 109:536-546.
32. Lukacs NW, Berlin A, Schols D, et al. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160:1353-1360. An interesting study investigating a novel antagonist.
33. Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002; 295:336-338. An excellent murine study showing one of the functions of T-bet.
34. Kaplan MH, Grusby MJ. Regulation of T helper cell differentiation by STAT molecules. J Leukoc Biol 1998; 64:2-5.
35. Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4 induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380:630-633.
36. Wang LH, Yang XY, Kirken RA, et al. Targeted disruption of Stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4 driven TH2 response. Blood 2000; 95:1249-1257.
37. Adachi T, Stafford S, Sur S, Alam R. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J Immunol 1999; 163:939-946.
38. Gorska MM, Alam R. Signaling molecules as therapeutic targets in allergic disease. J Allergy Clin Immunol 2003; 112:241-250. An elegant review of the possible therapeutic targets in allergic disease.